| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 1.3MM | +10% |
| Gross Profit | 848K | +8% |
| Cost Of Revenue | 469.8K | +11% |
| Operating Income | -1.9MM | -5% |
| Operating Expenses | 2.7MM | -1% |
| Net Income | -1.6MM | -7% |
| R&D | 732.4K | +24% |
| G&A | 1.1MM | -8% |
| Marketing | 860.6K | -9% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Key Insights NeuroMetrix to hold its Annual General Meeting on 30th of April CEO Shai Gozani's total compensation...
Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN). Hayashi and colleagues evaluated 167 patients with Type 1 or Type 2 diabetes. The reference standard for DPN was a gold standard nerve conduction study. The authors developed a predictive formula based on DPNCheck measurements, patient age
WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. “We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “This early adoption affirms the
NURO stock price has declined 99% since its IPO Gozani has received compensation of over $10 million since the IPO Gozani was charged by the FTC for various wrongdoings at NURO Gozani apparently personally paid the FTC $4 million as part of a settlement ...
Stock trades significantly below its net cash per share. The board is arguably in breach of their fiduciary responsibility to protect shareholder value. Operating any capital raise at current price is grossly irresponsible and against shareholders ...
- Stock trades significantly below its net cash per share - Questions the Board's ability and/or desire to create shareholder value - Notes tremendous destruction of shareholder value under company's leadership - Sees no reason for company to remain ...
NeuroMetrix ( NASDAQ:NURO ) Full Year 2023 Results Key Financial Results Revenue: US$5.90m (down 28% from FY 2022). Net...
NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript February 22, 2024 NeuroMetrix, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the NeuroMetrix Fourth Quarter 2023 Business and Financial Update. My name is Josh, and […]
Q4 2023 NeuroMetrix Inc Earnings Call